My PCR Releases New Resource on Treatment Free Remission (TFR)
My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).
Welcoming our New Vice President of Development
The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation.
Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives.
Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.
“As an ambitious organization, we knew we needed a leader with a breadth of experience who can push us to the next level,” says Patti Pearce, The Max Foundation CFO and VP of Administration. “I have total confidence in Wilma’s leadership and experience to drive success.”
Wilma will join The Max Foundation’s Seattle headquarters office and oversee The Max Foundation’s development and communication departments.
“I am honored to have the opportunity to join The Max Foundation,” says Wilma. “I’ve been impressed with the organization from the start and feel connected to the mission of providing dignity and hope to cancer patients worldwide.”
Please join us in welcoming Wilma Comenat as The Max Foundation’s Vice President of Development.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
The Max Foundation Announces CancerPath to Care to Treat Up to 36,000 People Living with Leukemia, Breast and Certain Rare Cancers in Over 70 Low- and Middle-income Countries by 2025
New initiative expands existing collaboration with Novartis focused on chronic myeloid leukemia and other rare cancers, to support patient access to care for breast cancer, the leading cause of death in women globally
Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC
The Max Foundation CEO recognized for unwavering dedication to global, widespread health equity